TITLE:
Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial
AUTHORS:
Linda Battalora, Amy Thomas, Brian Wine, Belinda Ha, Benjamin Young
KEYWORDS:
Bonedensity; Abacavir; HIV; Integrase; Lamivudine; Raltegravir
JOURNAL NAME:
World Journal of AIDS,
Vol.4 No.1,
March
4,
2014
ABSTRACT:
Decreased bone mineral
density (BMD) and osteoporotic fractures are areas of increasing concern among
HIV-infected persons. Particular concern is the rapid decline in BMD after
initiation of antiretroviral treatment (ART). This report describes
DEXA-assessed changes in BMD and body fat in a study of fifteen
antiretroviral-na?ve adults initiating abacavir/lamivudine and raltegravir for 96
weeks. Median percent changes from baseline at weeks 48 and 96 in BMD were
0.29% and -0.11% (spine); -1.25%
and -1.75% (left hip). Median percent changes from
baseline in fat from baseline were -0.82%
and -3.04% (trunk); 2.12% and 2.01% (limb). In
this pilot study, ABC/3TC + RAL treatment had limited impact on BMD and body
fat.